Introduction
The serine-threonine kinase AKT plays a central role in multiple cellular processes important to carcinogenesis, making it an attractive anti-cancer therapeutic target.
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The PI3K/AKT pathway also plays an evolutionarily-conserved role in glucose metabolism where it acts to transduce intracellular signals downstream of insulin and the insulin-like-growth factor. 3 The three AKT isoforms (AKT1, 2 and 3) are highly homologous yet differ in quantitative levels of tissue-specific expression, which determines the relative contribution of each isoform to glucose metabolism and insulin signaling. 4, 5, 6 GSK2141795 is a potent, oral, ATP-competitive inhibitor of all three AKT isoforms. In the first-time-in-human (FTIH) study, the maximum tolerated dose of GSK2141795 was 75mg daily; however the level of tumor target engagement at this dose was not elucidated. The study described in this manuscript was designed to answer this question.
Preclinical data indicate that knockout of AKT2 in mice results in insulin resistance with a diabetes-mellitus like syndrome. 7, 8 In contrast; AKT1-deficient mice display an opposing phenotype with increased insulin sensitivity. 9 AKT also has a direct effect on tumor glucose metabolism by stimulating aerobic glycolysis and survival. Tumors with PI3K/AKT pathway activation have robust [ This study hypothesized that inhibition of glucose uptake visualized by FDG-PET imaging could be used as a PD marker of AKT inhibition at the tumor level; and that if a relationship could be established between GSK2141795 exposure and glucose inhibition in tumors, FDG-PET imaging could be used as a surrogate marker of GSK2141795 PK. In this way FDG-PET imaging could enable a physician to personalize dosing of GSK2141795 and theoretically optimize the risk/benefit profile for each patient.
The primary objective of this study was to explore the relationship between changes in glucose metabolism at the tumor level [FDG-PET], and systemically [1,5-anhydroglucitol (1,5-AG)], with pharmacokinetic parameters of GSK2141795 exposure. Secondary objectives included characterization of PK, safety, tolerability and clinical activity of GSK2141795. Additional exploratory objectives included (1) evaluation of paired pretreatment and on-treatment tumor biopsies using immunohistochemistry (IHC) and reverse phase protein array (RPPA) to explore the association of changes in tumor glucose uptake seen on FDG-PET imaging with changes in the PI3K/AKT pathway and (2) evaluation of tumor tissue for genetic markers of pathway activation (e.g. KRAS mutation, PIK3CA mutation, etc) as potential predictive markers of response to GSK2141795.
Materials and Methods

Patient Population
This was an open-label, 2-stage, Phase-I study conducted at Imperial College London.
FDG-PET imaging was conducted at the GlaxoSmithKline Clinical Imaging Centre. The protocol and informed consent document were approved by the West London
Research Ethics Committee and registered as NCT01266954 at ClinicalTrials.gov.
Approval was also obtained from the UK Administration of Radioactive Substances Advisory Committee. All subjects provided written informed consent.
Study Design
The study was conducted in two stages; stage 1 evaluated whether continuous dosing of GSK2141795 would confound interpretation of sequential FDG-PET scans and whether FDG-PET could be used as an imaging biomarker for AKT-targeted therapy.
Stage 2 assessed dose-response relationships between GSK2141795 and tumor metabolism using sequential PET scans. The study design and decision making algorithm for progression from Stage 1 to Stage 2 is included in SD-1.
Study Drug Administration
Twelve patients were enrolled in the study. Four were enrolled in Stage 1 and administered 50mg oral GSK2141795 daily for 4 weeks (Cohort 1) followed by dose escalation to 75mg daily. Four additional patients were enrolled in each of 2 sequential cohorts of 75mg daily continuously (Cohort 2), or 25mg for 2 weeks followed by dose escalation to 75mg daily (Cohort 3). On the day of the W2 and W4 scans, GSK2141795
was administered 2-3 hours before scan start to ensure that the scan was performed at Cmax (maximum plasma concentration). Dose modifications were made for clinically significant adverse events (AE) as determined by the investigator. Specific dose modification guidelines were provided for QTc prolongation, liver chemistry abnormalities, hypoglycemia and hyperglycemia.
Study Assessments
Study assessments included collection of archival tumor samples, safety evaluations, 
Pharmacokinetics
Plasma samples were analyzed using a validated method based on liquid-liquid extraction followed by high-pressure liquid chromatography-mass spectrometry/mass spectrometry analysis. The lower and higher limits of quantification for GSK2141795
were 1ng/mL and 1000ng/mL respectively using a 100μL aliquot of human plasma.
GSK2141795 plasma concentrations and actual sample time data were analyzed using non-compartmental methods (WinNonlin V6.3). 
Quantitative FDG-PET
Exploratory Biomarker Studies
Three core biopsies were taken at pre-treatment and W4 for each patient; two were fixed (one formalin fixed/paraffin embedded (FFPE), one ethanol (70%) fixed) and one was fresh frozen for mutation and proteomic analysis. 15, 16 Fixed samples were assessed for tumor cellularity, heterogeneity, and expression levels of candidate PD biomarkers by immunohistochemistry (IHC). Analyses were performed by Mosaic
Laboratories (Lake Forest, CA USA) and Imperial College London Histopathology Laboratories using standard methods and antibodies as outlined in ST 2.
Following intra and inter-biopsy heterogeneity assessment of paraffin-embedded biopsies as a reference point, RPPA data derived from the fresh frozen biopsies (pretreatment and W4), were generated as described previously 17 (MD Anderson Cancer
Center, TX, USA) and evaluated for changes in AKT and phosphoAKT.
DNA was isolated from archival FFPE samples (Response Genetics, Los Angeles, California, US) and analyzed (Expression Analysis, Durham, North Carolina, US) using a custom genotyping assay on the Illumina Golden Gate platform covering 78 genes and 480 probes/mutations (ST 3). DNA was also isolated from cell pellets produced during protein extraction and from archival FFPE paraffin shavings. These samples were subjected to hot spot mutation detection by a mass spectroscopy-based approach evaluating single nucleotide polymorphisms using Sequenom's MassARRAY platform covering 17 genes and 147 mutations at MD Anderson Cancer Center (ST 4).
Tumor Response Evaluation
Tumor response was evaluated according to RECIST (Response Evaluation Criteria for Solid Tumors) 1.1 15 and the 2005 Gynecological Cancer Intergroup (GCIG) criteria for CA125 (which was not prospectively defined in the protocol).
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Statistics
For FDG-PET analyses using SUVmax(60-90), Ki, and MRfdg, raw and mean values (over tumor locations) for each patient at each time point were descriptively explored.
Post-baseline mean and percent-change from baseline of the mean PET parameters (across tumor locations) were considered missing if any baseline tumor location was missing post-baseline. GSK2141795 PK parameters were summarized descriptively.
Exploratory analyses including simple linear regression models were performed to assess the potential relationship between GSK2141795 exposure and PD endpoints including changes in FDG-PET parameters and 1,5-AG. IHC and genetic mutation data were each descriptively explored. RPPA data was investigated post hoc; paired ttests comparing pre-treatment and W4 AKT and phospho-AKT protein expression levels were evaluated.
Results
Patient characteristics
Twelve patients (11 ovarian and 1 endometrial) were enrolled between June and November 2010 (median age 64.5 years, range 45 to 78 years). All ovarian cancer patients were platinum resistant 17, 18 and had received at least 1 line of prior therapy (median 3.5 lines). 8/11 (73%) of the patients with ovarian cancer had serous histology and all had measurable disease.
Safety and tolerability
Of the 12 patients enrolled, 3 were withdrawn because of an AE and 9 were withdrawn due to disease progression. 9 patients had GSK2141795 interrupted due to AEs (3 'being drug related) and 2 patients were dose-reduced due to AEs. All patients reported at least one AE, with nausea and lethargy being the most commonly reported (Table 1) .
7 patients experienced Grade 3/4 AEs (four Grade 3 AEs were attributed to study drug).
Three Grade 4 events (renal failure, thrombocytopenia and vomiting) were reported in 2 patients. No fatal events were reported on study drug.
Pharmacokinetic Results
Since the majority of patients only had PK sampling up to 5 hrs post-dose (the optional when the same dose was given for 4 weeks, suggesting that GSK2141795 was not at steady state in all patients at W2 ( Table 2 ). The apparent half-life is approximately 2 to 4 days.
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FDG-PET Analysis
All 12 patients administered GSK2141795 underwent dynamic FDG-PET scans. PET scans were not obtained on W4 for three patients; W2 PET scan for one patient was validated the use of IDF to derive quantitative parameters precluding the need to obtain further radial arterial samples in subsequent cohorts.
Although there was considerable heterogeneity in FDG uptake (Ki, SUVmax(60-90) and MRfdg) among individual tumors in each patient ( Figures 1A-C) , the mean change from W2 to W4 SUVmax(60-90) in the 3 Stage 1 patients who had both W2 and W4 scans was <15%. This observation suggested that changes in FDG uptake from W2 to W4
were within physiological variability and unlikely to be due to the cumulative effect of continuous repeat doses of GSK2141795.
All patients had pre-PET scan fasting blood glucose levels < 7.5 mmol/L. Overall, the impact of blood glucose on tumor FDG measurements was predicted to be minimal, an observation supported by the high degree of correlation between SUVmax(60-90) and the quantitative parameter Ki, (r 2 = 0.89) ( Figure 1D ).
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PK/PD Analysis
The potential exposure-response relationships between various PK parameters for GSK2141795 and both tumor and systemic markers of glucose metabolism were explored.
FDG-PET
The strongest linear relationships between PK and FDG-PET PD parameters were 
Exploratory Biomarker Studies
Archival samples were collected from all patients enrolled on the trial. Core biopsies were performed as follows: Pre-treatment (n=12); Week 4 (n=10). Of the 58 core biopsies obtained; only one complication, a self-limiting intra-abdominal hematoma, was encountered (1.7%).
Proteins
AKT protein levels in paired biopsies (pre-treatment and W4 on-treatment) were evaluated by RPPA and IHC. Decreases in total AKT (p=0.05) and increases in the phospho-AKT/total AKT ratio (p=0.05) at W4 compared to baseline by RPPA were observed across all patients regardless of response to GSK2141795, an observation consistent with PD target engagement. 
Clinical Response
All 12 patients had measureable disease by RECIST; one partial response (PR) was reported (overall response rate 8%) although 2 additional patients continued on trial for >6 months (clinical benefit rate 25%) (Figure 3) . 10 of 11 patients with ovarian cancer were evaluable based upon CA125 GCIG criteria 11 ; 3/10 had a CA125 response.
Discussion
GSK2141795 is an oral nanomolar pan-AKT kinase inhibitor which influences glucose uptake and inhibits cellular proliferation in preclinical cell line and xenograft models. 
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Unfortunately, the heterogeneity in FDG uptake between the various tumors both within and between individual patients, as well as the amount of overlap between the PK parameters measured at each dose negated a more easily generalizable dose-response relationship. It is not surprising that significant variation was seen in FDG uptake by individual tumors given recent data suggesting significant intra-tumor spatial and linear heterogeneity. 25, 26, 27 As AKT inhibition by GSK2141795 can cause hyperglycemia, 7, 8, 9, 10,11 thereby altering FDG tissue uptake, we acquired dynamic FDG-PET scans to derive quantitative PET parameters which can account for the confounding effects of plasma glucose levels and scan timing. 14 Although hyperglycemia adverse events and decreased 1,5-AG levels were observed in this study, fasting blood glucose levels measured prior to scans were within limits unlikely to affect the evaluation of FDG uptake in tumors using semi- There are some caveats to this study that could influence interpretation of the results.
Firstly, it is possible that the changes in FDG-PET avidity seen in tumors at W2 and W4 
